Zomedica Announces Letter From Robert Cohen, Interim CEO, Made Available to Shareholders in Connection With Special Virtual-Only Meeting
ANN ARBOR, Mich., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) announced today that the following letter from Robert Cohen, Interim Chief Executive Officer, has been made available to shareholders.
I am writing to you today with a single, straightforward message -- please vote for the domestication proposal described in our proxy materials for our virtual Special Meeting to be held on December 15, 2020. Approval of the domestication proposal will enable Zomedica to reincorporate the company in Delaware, as opposed to its present incorporation in Alberta, Canada.
Management believes that reincorporating your company in Delaware will directly benefit shareholders by saving approximately $500,000 per year in duplicative, unnecessary compliance costs.
We believe that effecting the domestication also will enhance shareholder value over the long term by, among other things, making our company more attractive to institutional investors who are more comfortable investing in a Delaware corporation. In addition, our corporate offices and operations are located in the United States and a large percentage of our shareholders now are located there.
If your common shares are held by a broker, bank or other intermediary, you will need to obtain a voting instruction form from the organization that holds your common shares and follow the instructions included on that form regarding how to instruct the organization to vote your common shares.
Once again, I would appreciate your vote in favor of the domestication. Your Board of Directors and management all believe that it is in the best interests of Zomedica and our shareholders.
Additional Information and Where to Find It
Participants in the Solicitation
No Offer or Solicitation
Investor Relations Contact: